Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

Opioid Use Disorder Clinical Trial

— Pharm-OUD-Care  

Official title:

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: Clinical Trials Network 0075

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03248947
• Other study ID #: Pro00083544
• Secondary ID: UG1DA040317
• Status: Completed
• Phase: Early Phase 1
• Start date: March 28, 2018
• Est. completion date: June 27, 2019

Study information

• Verified date: July 2021
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study examines the feasibility and acceptability of transitioning office-based buprenorphine treatment of opioid use disorder from physicians to pharmacists. Results from this study will inform the development of a future multi-site randomized clinical trial.

Description:

The overall objective of this study is to explore the feasibility of transitioning the care of adult patients with opioid use disorder (OUD) who receive office-based buprenorphine treatment (OBBT) from physicians to pharmacists. Physicians will induce buprenorphine treatment and complete the stabilization phase before referring patients to pharmacists for the management of monthly maintenance visits. This study will assess the feasibility and acceptability of a collaborative care model between physician and pharmacist by measuring recruitment rate, treatment retention rate, treatment compliance rate, and participants' substance use. Other assessments measured will include treatment fidelity, participant, physician, and pharmacist satisfaction with OUD care, participant safety, and the pharmacists' use of electronic health records and the Prescription Drug Monitoring Program.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: June 27, 2019
• Est. primary completion date: June 27, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be adults aged 18 years or older.
• If female, use adequate birth control methods.
• Meet DSM-5 criteria for past-year OUD and have completed buprenorphine induction for OUD.
• Have expressed the intention to receive maintenance (=6 months) buprenorphine treatment.
• Be willing to receive pharmacist administered buprenorphine maintenance treatment
• Be willing and able to provide written informed consent and HIPAA authorization.
• Be able to read and communicate in English.
• Be able to comply with buprenorphine treatment policies.

Exclusion Criteria:

• Have a serious medical, psychiatric or substance use disorder that, in the opinion of the study physician, would make study participation hazardous to the participant, compromise study findings, or prevent the participant from completing the study.
• Have known allergy or hypersensitivity to buprenorphine, naloxone, or other components of the buprenorphine/naloxone formulation.
• Have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) liver enzymes greater than 5 times the upper limit of normal on screening phlebotomy performed within 60 days prior to the date of the last stabilization visit.
• Have chronic pain requiring ongoing pain management with opioid analgesics.
• Pending legal action or other reasons that might prevent an individual from completing the study (i.e., unable to complete 6 months of pharmacy-based OUD management).
• Pregnant or breastfeeding at the time of screening.

Related Conditions & MeSH terms

• Disease
• Opioid Use Disorder
• Substance-Related Disorders

Intervention

Drug:
• buprenorphine/naloxone
To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.

Other:
• Pharmacist-administered buprenorphine/naloxone maintenance care
Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.

Locations

Country	Name	City	State
United States	Changes by Choice	Durham	North Carolina
United States	Clinic Pharmacy	Durham	North Carolina
United States	Duke Outpatient Clinic	Durham	North Carolina
United States	Josefs Pharmacy	Durham	North Carolina
United States	Carolina Performance	Raleigh	North Carolina
United States	Health Park Pharmacy	Raleigh	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Duke University	National Institute on Drug Abuse (NIDA), The Emmes Company, LLC

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wu LT, John WS, Ghitza UE, Wahle A, Matthews AG, Lewis M, Hart B, Hubbard Z, Bowlby LA, Greenblatt LH, Mannelli P; Pharm-OUD-Care Collaborative Investigators. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use d — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recruitment Rate	Measured by a composite of the number of participants with opioid use disorder recruited (i.e., signed the informed consent form) per month, and by site and the average monthly rate of participants enrolled among potential participants who were screened.	Up to six months
Primary	Treatment Retention	Number of scheduled visits completed.	Up to six months
Primary	Number of Participants With Opioid and Other Substance Use	Measured via a composite of urine drug screen (UDS) and self-report via Timeline Follow-Back over 30 days.	Up to six months
Primary	Number of Medication-Compliant Months Across All Participants	Medication compliance is defined as taking any of the dispensed medication during the past month as measured by pill count/dose reconciliation at each study visit. Medication compliance is calculated as the percentage of compliant months out of the overall number of expected study months.	Up to six months
Secondary	Treatment Fidelity	Number of monitored study visits with physicians and pharmacists showing 80% adherence or higher to study specific tasks and responsibilities. Adherence will be calculated as the number of items completed on the Buprenorphine Visit Checklist divided by the sum of the number of complete and incomplete items.	Up to six months
Secondary	Treatment Satisfaction	Indicators of satisfaction with treatment delivery measured by participants, pharmacists, and physicians using the Treatment Satisfaction Scale after each study visit. A score of 5=very satisfied, 4=satisfied, 3=neither satisfied or dissatisfied, 2=dissatisfied, and 1=very dissatisfied.	Up to six months
Secondary	Participant Safety	A composite of self-report and medical record abstraction to measure any fatal or non-fatal opioid overdose and any opioid or other substance-related emergency department visit or hospitalization.	Up to six months
Secondary	Pharmacists' Use of the Prescription Drug Monitoring Program (PDMP)	Measured at each study visit via an action item checklist to confirm whether the PDMP was inquired to identify the following for each participant: measures of multiple buprenorphine prescriptions, any prescriptions for class II and III medications, and any other information that may be useful for the participant's treatment such as documented drug-related medical interventions or disciplinary charges.	Up to six months